Here are JPMorgan’s top drug stock picks into earnings

Daniel Acker | Bloomberg | Getty Images

Bottles of Eli Lilly’s Cymbalta on a pharmacy shelf in Princeton, Illinois.

JPMorgan’s research team named its favorite pharmaceutical picks ahead of second quarter earnings releases.

Given recent rotation back into the sector, JPMorgan analysts “wanted to share our latest thoughts on key incoming questions for our Speciality & Major Pharma coverage,” they wrote on Wednesday.

Here are three companies that JPMorgan recommended.